Analyst Conference Summaries

Biotechnology Investor Aids

conference date: November 14, 2024 @ 1:30 PM Pacific Time

Inovio: Hold for Future DNA Plasmid Therapy Progress [January 10, 2023, Seeking Alpha]

Inovio Has 4 Sources Of Potential Value [June 2, 2021, Seeking Alpha]

Inovio VGX-3100 HPV Data Adds To Conviction [March 24, 2021 at Seeking Alpha]

more articles below

Inovio: Accumulate For The HPV And Brain Cancer Therapies [November 19, 2020 at Seeking Alpha]

Inovio's Wild Ride and Real Value [March 24, 2020 at Seeking Alpha]

Inovio's dBiTEs Technology Data Adds To Buy Conviction [April 23, 2019 at Seeking Alpha]

Inovio Pharmaceuticals: Roth Capital $13 Target Evaluated [December 30, 2019 at Seeking Alpha]

Inovio: Time To Think About 2020 [July 11, 2018 at Seeking Alpha]

Why Inovio Surged 13% This Week [May 19, 2017 @ Seeking Alpha]

Inovio's Zika Vaccine is not its Most Attractive Asset [March 24, 2016 @ Seeking Alpha]

Inovio's dMAb Technology [June 17, 2015 @ Seeking Alpha]

Cramer Interviews Inovio CEO Joseph Kim [June 8, 2017 @ youtube]

Zika Vaccine First Patient Dosed [Inovio release July 26, 2016]

MedImmune Licenses Inovio HPV DNA Vaccine [Inovio release August 10, 2015]
Will Inovio's Deal With Roche Lead To A Cancer Blockbuster? [August 15, 2014 @ SA]
Inovio DNA-Based Monoclonal Antibody for Dengue Positive Preclinical Results [Inovio press releae July 29, 2015]
Inovio Gets Positive HPV Therapy Results [July 23, 2014 at Seeking Alpha]
Inovio's Price Spike and the Future of DNA Vaccines [August 17, 2013]
Inovio Pharmaceuticals' H7N9 Vaccine Protects 100% Animals in Study [July 8, 2013]
Sorting Out Inovio Claims [June 12, 2013]
Inovio's Promising Vaccine Data [December 17, 2012]
Inovio Prospects [June 18, 2012]
I buy Inovio [May 21, 2012]

Inovio Pharmaceuticals (INO) is a development-stage biotechnology company specializing in DNA-based vaccine delivery.

Inovio web site
Inovio investor relations page

OpenIcon Analyst Conference Summaries Main Page

Search

More Analyst Conference Pages: